Fig 1: Elevated IGF2BP2 expression correlates with poor prognosis of patients with HCC. (A) METTL3 (left) and IGF2BP2 (right) mRNA levels in the TCGA databases. (B) Kaplan-Meier survival curves of OS based on METTL3 and IGF2BP2 expression using the online bioinformatics tool GEPIA. (C) Representative IHC images of IGF2BP2 protein expression in HCC tissues (T) and adjacent normal tissue (N) of two patients (P1–P2). (D) IGF2BP2 protein levels were measured in HCC tissues and paired normal tissues by western blotting. (E) An m6A RNA methylation assay revealed the m6A content in HCC tissues and adjacent normal tissues. (****P < 0.0001, Student’s t-test).
Fig 2: IGF2BP2 regulates EMT program of HNSCC cells. A FaDu and SCC15 cells were either treated with TGF-β (10 ng/ml) or without. Cell morphologic changes were observed after 72 h. Representative images from 3 independent experiments are shown. Scale bars: 200 μm. B FaDu and SCC15 cells were either treated with TGF-β or without. Cytoskeleton alterations were assessed by immunofluorescence staining with phalloidin, and by confocal scanning after 72 h. White arrows indicate the extensive filopodia and lamellipodia. Representative images from 3 independent experiments are shown. Scale bars: 50 μm. C The results of the western blot analysis of the expression of E-Cadherin in FaDu and SCC15 cells either treated with TGF-β or without. Right panel shows the statistical analysis of western blot. **P < 0.01, ***P < 0.001. D-E FaDu and SCC15 cells underwent transfection with si-RNAs or si-NC after TGF-β treatment. The levels of E-Cadherin, N-Cadherin, and vimentin expression were identified with RT-qPCR (D) and western blotting (E). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. F FaDu and SCC15 cells were transfected with si-RNAs or si-NC after TGF-β treatment. The expression and distribution of E-Cadherin and vimentin was identified by immunofluorescence and confocal scanning. Red: E-Cadherin; Green: vimentin; Blue (DAPI): nuclei. Scale bars: 100 μm. Right panel shows the statistical analysis of immunofluorescence. ***P < 0.001, ****P < 0.0001. G-H FaDu and SCC15 cells were transduced with IGF2BP2 and a corresponding control vector, without TGF-β treatment. The expression levels of E-Cadherin, N-Cadherin, and vimentin were identified with RT-qPCR (G) and western blotting (H). **P < 0.01, ***P < 0.001, ****P < 0.0001. All the data are presented in the form of mean ± SD from three independently performed experiments
Fig 3: Silencing of lncRNA MALAT1 Inhibits MYC Expression and TC Tumor Growth In Vivo by Downregulating IGF2BP2SW579 cells were treated with sh-NC + oe-NC, sh-MALAT1 + oe-NC, or sh-MALAT1 + oe-IGF2BP2 and then transplanted into nude mice. (A–C) The representative images of xenograft tumors and quantitative analysis of tumor weight and volume. (D) Expression patterns of MYC in tumor sections identified by immunohistochemical staining (original magnification 200×). (E) Cell apoptosis in tumor tissues detected by TUNEL assay (original magnification 200×). (F) Expression patterns of miR-204, lncRNA MALAT1, IGF2BP2, and MYC in mice detected by qRT-PCR and normalized to U6 and GAPDH, respectively. Data (mean ± standard deviation) among multiple groups were compared with one-way ANOVA, followed by Tukey’s post hoc test. n = 6. ∗p < 0.05.
Fig 4: IGF2BP2 Promotes MYC Expression by Recognizing the m6A Modification of MYC in TC Cells(A) Western blot analysis of MYC protein levels in Nthy-ori 3-1 and SW579 cells, normalized to GAPDH. (B) The silencing efficiency determined by western blot analysis. (C) m6A modification levels of MYC and m6A expression in cells after METTL14 silencing measured by Me-RIP and IP assays. (D) Western blot analysis of MYC protein levels in METTL14-silenced cells, normalized to GAPDH. (E) Binding of IGF2BP2 to MYC assessed by RIP assay. (F) Western blot analysis of MYC and IGF2BP2 protein levels in IGF2BP2-silenced cells, normalized to GAPDH. Data (mean ± standard deviation) were compared with unpaired t test. The experiment was repeated three times independently. ∗p < 0.05.
Fig 5: lncRNA MALAT1 Binds to miR-204, Leading to Upregulated IGF2BP2 Expression in TC Cells(A) lncRNA MALAT1 expression patterns in TC cells determined by qRT-PCR, normalized to GAPDH. (B) Cellular localization of lncRNA MALAT1 detected by fractionation of nuclear/cytoplasmic RNA. (C) The binding of miR-204 to lncRNA MALAT1 confirmed by dual-luciferase reporter gene assay. (D) The enrichment of miR-204 and lncRNA MALAT1 in Ago2 and IgG detected by RIP assay. (E) Expression of miR-204 and lncRNA MALAT1 in TC cells after inhibition of miR-204 and lncRNA MALAT1 determined by qRT-PCR, normalized to U6. (F) Western blot analysis of IGF2BP2 protein levels in TC cells after inhibition of miR-204 and lncRNA MALAT1, normalized to GAPDH. Data (mean ± standard deviation) between two groups were compared using unpaired t test, while those among multiple groups were compared with one-way ANOVA, followed by Tukey’s post hoc test. The experiment was repeated three times independently. ∗p < 0.05.
Supplier Page from Abcam for Anti-IGF2BP2/IMP-2 antibody [1E3.01E5]